WO2013159419A1 - Utilisation de plasma séminal - Google Patents

Utilisation de plasma séminal Download PDF

Info

Publication number
WO2013159419A1
WO2013159419A1 PCT/CN2012/076042 CN2012076042W WO2013159419A1 WO 2013159419 A1 WO2013159419 A1 WO 2013159419A1 CN 2012076042 W CN2012076042 W CN 2012076042W WO 2013159419 A1 WO2013159419 A1 WO 2013159419A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
seminal plasma
sample
cells
plasma protein
Prior art date
Application number
PCT/CN2012/076042
Other languages
English (en)
Chinese (zh)
Inventor
李偃
程辉
Original Assignee
陕西精健新星生物医药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陕西精健新星生物医药有限公司 filed Critical 陕西精健新星生物医药有限公司
Publication of WO2013159419A1 publication Critical patent/WO2013159419A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • the invention relates to the use of seminal plasma.
  • Tumors are caused by imbalances in cell electron balance.
  • Reactive oxygen free radical ROS
  • ROS reactive radical
  • a substance that lacks electrons (unsaturated electronic matter) When it enters the human body, it competes for electrons everywhere. If the electrons of the cellular protein molecule are taken away, the protein is branched and thiolated, and distortion is formed. The molecule is carcinogenic. Because of the lack of electrons, the distorted molecules have to capture the electrons of neighboring molecules, and the neighboring molecules are also distorted and carcinogenic. In this way, the vicious circle will form a large number of distorted protein molecules. When these distorted protein molecules multiply, the gene mutations form a large number of cancer cells, and finally cancer symptoms appear.
  • Patent CN200710017785.3 has described the application of animal semen medicine in the treatment of various diseases such as tumors and depression, while semen includes seminal plasma and sperm, and seminal plasma is secreted by prostatic fluid, seminal vesicle fluid, epididymal fluid and urethral gland. The small amount of liquid is composed together.
  • the seminal plasma is the necessary medium for transporting sperm and provides energy and nutrients for the sperm.
  • the seminal plasma is secreted by the prostate, seminal vesicles and urethral glands.
  • the seminal plasma contains fructose and protein, which is the nutrition of sperm.
  • Substance, seminal plasma also contains prostaglandins and some enzymes, is a natural organic substance, no toxic side effects.
  • the new use of the seminal plasma provided by the present invention is mainly used for inhibiting the spread of cancer cells, especially larger than
  • the 3kDa seminal plasma protein has a very obvious inhibitory effect on the proliferation of cancer cells.
  • Seminal plasma is used to inhibit the spread of cancer cells, and seminal plasma is used to inhibit the spread of cancer cells such as lung cancer cells, breast cancer cells, colon cancer cells, cervical cancer cells, liver cancer cells or gastric cancer cells.
  • Seminal pulp is a pharmaceutical preparation of the active ingredient.
  • Seminal pulp is used to prepare capsules, granules, tablets, dropping pills, Chinese and Western medicine compound preparations, oral liquids or injection solutions.
  • the seminal plasma protein is used to inhibit the spread of cancer cells, and the seminal plasma protein is used to inhibit the spread of cancer cells such as lung cancer cells, breast cancer cells, colon cancer cells, cervical cancer cells, liver cancer cells, or gastric cancer cells.
  • a seminal plasma protein is a pharmaceutical preparation of the active ingredient.
  • seminal plasma protein in the preparation of a medicament for treating cancers such as lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer.
  • Seminal pulp is used to prepare capsules, granules, tablets, dropping pills, Chinese and Western medicine compound preparations, oral liquids or injection solutions.
  • the above seminal plasma proteins are more effective.
  • the present invention has acquired the application of fine pulp in the treatment of cancers such as lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer through a large number of experimental studies and breaking through the limitations of the prior art application.
  • the present invention has found through experiments that the effect of inhibiting cancer cells is also related to the molecular diameter of seminal plasma protein in seminal plasma and the concentration of seminal plasma.
  • the inhibitory effect of seminal plasma protein molecules greater than 3 kDa is obvious, seminal plasma concentration or seminal plasma protein concentration.
  • the effect is generally 2.5% ⁇ 5.0%, 5.0% ⁇ 7.5% is better, and the inhibition is obvious after more than 7.5% ⁇ 10.0%.
  • the seminal plasma can be prepared into various preparations such as capsules, granules, tablets, dropping pills, oral liquids, and injection solutions, and is preferably used as a capsule.
  • This product can also be used in combination with other drugs to make Chinese and Western medicine compound preparations. detailed description
  • RPMI-1640 medium is a Thermo company (Beijing) product; fetal bovine serum is Thermo public Division (Beijing) product; MTT is Invitrogen product; the rest of the reagents are imported analytically pure; phosphate buffered saline solution (PBS): NaCl 8g, KC1 0.2g, Na 2 HP0 4 1.44g, KH 2 P0 4 0.24g, dissolved Adjust the pH to 7.4 at 800ml ddH 2 O, dilute to 1L, autoclave at 121 °C,
  • trypsin solution 1.25 g of trypsin, dissolved in 500 ml of PBS, and stored at 4 ° C after filter sterilization.
  • the sample is separated: After -20 °C, the solution is slowly thawed at 37 ° C. Under ice bath conditions, 2 ml of the sample is aspirated, centrifuged at 4 ° C, 3000 rpm for 10 min, and the semen sample is clearly layered, wherein the supernatant is seminal plasma. , transfer the seminal plasma into another EP tube, marked as "supernatant", the precipitated part is sperm, resuspended in 2ml PBS, labeled as "precipitate";
  • the target cell culture was carried out: Resuscitation NCI-H460-branch, cultured at 37 ° C, 5% C0 2 for 5 days until the cells proliferated to a certain amount, 0.25% trypsin digestion, and the cells were diluted to 1*10 5 cells in 1640 medium/ Ml, inoculated into 96-well plate, lOO L per well, continue to culture at 37 ° C, 5% C0 2 for 24 h until the cells are stably attached;
  • the microplate reader reads the sample mixture, the sample supernatant, the sample precipitate, the sample macromolecule, and the sample small molecule on the cell action readings, find the average value, and take the reading at the concentration of 0 For comparison, determine the percentage of inhibition according to the following formula:
  • Table 2 the sample has a lethal effect on tumor cells, especially after the concentration is greater than 10%, and the inhibition effect is obvious;
  • Table 3 to Table 4 show that after the sample is centrifuged, the supernatant is the seminal plasma part of the tumor cells. Significant lethal effect, and dose dependent, precipitation is sperm Some of the tumor cells have no obvious lethal effect;
  • Table 5 to Table 6 show that after the sample is separated by ultrafiltration centrifuge tube, the small molecule fraction less than 3kDa has no lethal effect on the tumor cells, while the macromolecular fraction greater than 3kDa Tumor cells have a lethal effect and are dose-dependent.
  • RPMI-1640 medium is Thermo (Beijing); fetal bovine serum is Thermo (Beijing); MTT is Invitrogen; other reagents are imported analytically pure; phosphate buffered saline (PBS): NaCl 8g, KC1 0.2g, Na 2 HP0 4 1.44g, KH 2 P0 4 0.24g, dissolved in 800ml ddH 2 O, HC1 adjust the pH to 7.4, dilute to 1L, autoclave at 121 °C,
  • trypsin solution 1.25 g of trypsin, dissolved in 500 ml of PBS, and stored at 4 ° C after filter sterilization.
  • the sample is separated: After -20 °C, the solution is slowly thawed at 37 ° C. Under ice bath conditions, 2 ml of the sample is aspirated, centrifuged at 4 ° C, 3000 rpm for 10 min, and the semen sample is clearly layered, wherein the supernatant is seminal plasma. , transfer the seminal plasma into another EP tube, marked as "supernatant", the precipitated part is sperm, resuspended in 2ml PBS, labeled as "precipitate";
  • the target cell culture was carried out: Resuscitation PA319-branch, cultured at 37 ° C, 5% C0 2 for 5 days until the cells proliferated to a certain amount, 0.25% trypsin digestion, and the cells were diluted to 1*10 5 /ml in 1640 medium.
  • the cells were transferred to a 96-well microtiter plate, and the absorbance was read at 490 nm per well.
  • the microplate reader reads the sample mixture, the sample supernatant, the sample precipitate, the sample macromolecule, and the sample small molecule interaction on the cells, and finds the average value, and takes the reading at the concentration of 0 as the control, according to the following formula. See the percentage of inhibition:
  • RPMI-1640 medium is Thermo (Beijing); fetal bovine serum is Thermo (Beijing); MTT is Invitrogen; other reagents are imported analytically pure; phosphate buffered saline (PBS): NaCl 8g, KC1 0.2 g, Na 2 HP0 4 1.44 g, KH 2 P0 4 0.24 g, dissolved in 800 ml ddH 2 O, adjusted to pH 7.4 with HCl, adjusted to 1 L, autoclaved at 121 ° C, and stored at 4 ° C.
  • PBS phosphate buffered saline
  • trypsin solution 1.25 g of trypsin, dissolved in 500 ml of PBS, and stored at 4 ° C after filter sterilization.
  • the sample is separated: After -20 °C, the solution is slowly thawed at 37 ° C. Under ice bath conditions, 2 ml of the sample is aspirated, centrifuged at 4 ° C, 3000 rpm for 10 min, and the semen sample is clearly layered, wherein the supernatant is seminal plasma. , transfer the seminal plasma into another EP tube, marked as "supernatant", the precipitated part is sperm, resuspended in 2ml PBS, labeled as "precipitate";
  • the target cell culture was carried out: Resuscitation Hela229-branch, cultured at 37 ° C, 5% C0 2 for 5 days until the cells proliferated to a certain amount, 0.25% trypsin digestion, and the cells were diluted to 1*10 5 /ml in 1640 medium.
  • the microplate reader reads the sample mixture, the sample supernatant, the sample precipitate, the sample macromolecule, and the sample small molecule interaction on the cells, and finds the average value, and takes the reading at the concentration of 0 as the control, according to the following formula. See the percentage of inhibition:
  • RPMI-1640 medium is Thermo (Beijing); fetal bovine serum is Thermo (Beijing); MTT is Invitrogen; other reagents are imported analytically pure; phosphate buffered saline (PBS): NaCl 8g, KC1 0.2 g, Na 2 HP0 4 1.44 g, KH 2 P0 4 0.24 g, dissolved in 800 ml ddH 2 O, adjusted to pH 7.4 with HCl, adjusted to 1 L, autoclaved at 121 ° C, and stored at 4 ° C.
  • PBS phosphate buffered saline
  • trypsin solution 1.25 g of trypsin, dissolved in 500 ml of PBS, and stored at 4 ° C after filter sterilization.
  • the sample is separated: After -20 °C, the solution is slowly thawed at 37 ° C. Under ice bath conditions, 2 ml of the sample is aspirated, centrifuged at 4 ° C, 3000 rpm for 10 min, and the semen sample is clearly layered, wherein the supernatant is seminal plasma. , transfer the seminal plasma into another EP tube, marked as "supernatant", the precipitated part is sperm, resuspended in 2ml PBS, labeled as "precipitate";
  • target cell culture Resuscitation MCF-7-branch, 37 ° C, 5% C0 2 culture for 5 days to self-cell proliferation to a certain amount, 0.25% trypsin digestion, 1640 medium to dilute the cells to 1 * 10 5 /ml Inoculate to 96-well plate, lOO L per well, continue at 37 ° C, 5% C0 2 culture for 24 h until the cells are stably attached and then dosing and testing: Add the sample according to the concentration shown in Table 1, each concentration Take 3 pairs of wells, culture at 37 ° C, 5% C0 2 for 24 h, then change the solution and gently wash the residual medium in the well with PBS. Add 5 ⁇ M of fresh medium to each well.
  • the microplate reader reads the sample mixture, the sample supernatant, the sample precipitate, the sample macromolecule, and the sample small molecule interaction on the cells, and finds the average value, and reads at a concentration of 0.
  • the percentage of inhibition was determined according to the following formula:
  • Table 2 the sample has a lethal effect on tumor cells, especially after the concentration is greater than 10%, and the inhibition effect is obvious;
  • Table 3 to Table 4 show that after the sample is centrifuged, the supernatant is the seminal plasma part of the tumor cells.
  • Significant lethal effect, and dose-dependent, precipitation, sperm fraction has no obvious lethal effect on tumor cells;
  • Table 5 ⁇ Table 6 shows that the sample is separated by ultrafiltration centrifuge tube, small molecule part less than 3kDa on tumor cells There is no obvious lethal effect, and the macromolecular part larger than 3kDa has obvious lethal effect on tumor cells, and has obvious dose-dependent.
  • RPMI-1640 medium is Thermo (Beijing); fetal bovine serum is Thermo (Beijing); MTT is Invitrogen; other reagents are imported analytically pure; phosphate buffered saline (PBS): NaCl 8g, KC1 0.2g, Na 2 HP0 4 1.44g, KH 2 P0 4 0.24g, dissolved in 800ml ddH 2 O, HCl adjusted to pH 7.4, constant volume to 1L, autoclaved at 121 °C,
  • trypsin solution 1.25 g of trypsin, dissolved in 500 ml of PBS, and sterilized by filtration and stored at 4 ° C.
  • the sample is separated: After -20 °C, the solution is slowly thawed at 37 ° C. Under ice bath conditions, 2 ml of the sample is aspirated, centrifuged at 4 ° C, 3000 rpm for 10 min, and the semen sample is clearly layered, wherein the supernatant is seminal plasma. , transfer the seminal plasma into another EP tube, marked as "supernatant", the precipitated part is sperm, resuspended in 2ml PBS, labeled as "precipitate";
  • the target cell culture was carried out: HepG2-branch was resuscitated, cultured at 37 ° C, 5% C0 2 for 5 days until the cells proliferated to a certain amount, 0.25% trypsin digestion, and the cells were diluted to 1*10 5 /ml in 1640 medium.
  • the microplate reader reads the sample mixture, the sample supernatant, the sample precipitate, the sample macromolecule, and the sample small molecule on the cell action readings, find the average value, and take the reading at the concentration of 0 For comparison, determine the percentage of inhibition according to the following formula:
  • Table 2 the sample has a lethal effect on tumor cells, especially after the concentration is greater than 10%, and the inhibition effect is obvious;
  • Table 3 to Table 4 show that after the sample is centrifuged, the supernatant is the seminal plasma part of the tumor cells.
  • Significant lethal effect, and dose-dependent, precipitation, sperm fraction has no obvious lethal effect on tumor cells;
  • Table 5 ⁇ Table 6 shows that the sample is separated by ultrafiltration centrifuge tube, small molecule part less than 3kDa on tumor cells There is no obvious lethal effect, and the macromolecular part larger than 3kDa has obvious lethal effect on tumor cells, and has obvious dose-dependent.
  • RPMI-1640 medium is Thermo (Beijing); fetal bovine serum is Thermo (Beijing); MTT is Invitrogen; other reagents are imported analytically pure; phosphate buffered saline (PBS): NaCl 8g, KC1 0.2 g, Na 2 HP0 4 1.44 g, KH 2 P0 4 0.24 g, dissolved in 800 ml ddH 2 O, adjusted to pH 7.4 with HC1, adjusted to 1 L, autoclaved at 121 ° C, and stored at 4 ° C.
  • PBS phosphate buffered saline
  • trypsin solution 1.25 g of trypsin, dissolved in 500 ml of PBS, and stored at 4 ° C after filter sterilization.
  • the sample is separated: After -20 °C, the solution is slowly thawed at 37 ° C. Under ice bath conditions, 2 ml of the sample is aspirated, centrifuged at 4 ° C, 3000 rpm for 10 min, and the semen sample is clearly layered, wherein the supernatant is seminal plasma. , transfer the seminal plasma into another EP tube, marked as "supernatant", the precipitated part is sperm, resuspended in 2ml PBS, labeled as "precipitate";
  • target cell culture Resuscitation SGC-7901-branch, 37 ° C, 5% C0 2 culture for 5 days until the cells proliferated to a certain amount, 0.25% trypsin digestion, 1640 medium diluted cells to 1 * 10 5 / Ml, inoculated into 96-well plate, lOO L per well, continue to culture at 37 ° C, 5% C0 2 for 24 h until the cells are stably attached;
  • the microplate reader reads the sample mixture, the sample supernatant, the sample precipitate, the sample macromolecule, and the sample small molecule on the cell action readings, find the average value, and take the reading at the concentration of 0 For comparison, determine the percentage of inhibition according to the following formula:
  • seminal plasma has a significant lethal effect on gastric cancer cells.
  • the technique for separating seminal plasma from semen is quite mature, and the technique for extracting seminal plasma from seminal plasma and screening molecular diameters larger than 3 kDa is quite mature, so the present invention mainly states that seminal plasma is cancerous. Inhibition of cells.
  • the present invention comprehensively analyzes the inhibitory effects of seminal plasma on lung cancer cells, breast cancer cells, colon cancer cells, cervical cancer cells, liver cancer cells or gastric cancer cells, and concludes that seminal plasma has obvious effects on cancer cells.
  • the conclusion of inhibition meanwhile, after further analysis of seminal plasma, the effect of inhibiting cancer cells is also related to the molecular diameter of seminal plasma protein in seminal plasma and the concentration of seminal plasma.
  • the inhibitory effect of seminal plasma protein molecules greater than 3kDa is obvious.
  • the plasma concentration or the concentration of seminal plasma protein is 2.5% ⁇ 5.0%
  • the effect is general, 5.0% ⁇ 7.5% is better, and the inhibition is obvious after more than 7.5% ⁇ 10.0%.
  • the specific data are related to the type of cancer cells inhibited. Example 1
  • Seminal plasma is prepared as the active ingredient.
  • the capsule is used for the treatment of lung cancer, breast cancer, colorectal cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma content is 52.5%.
  • Seminal granules prepared from active ingredients are used for the treatment of lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but are not limited to the above cancers, wherein the seminal plasma content is 60.2%.
  • a seminal plasma is a tablet prepared from active ingredients for the treatment of lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancers, wherein the seminal plasma content is 73.5%.
  • Semen pellets prepared by the active ingredient are used for the treatment of lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but are not limited to the above cancers, wherein the seminal plasma content is 81.9%.
  • Example 5
  • the seminal plasma is an oral liquid prepared by using an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma content is 90.1%.
  • the seminal plasma is an injection prepared by the active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma content is 77.3%.
  • the seminal plasma protein is a capsule prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content is 40.5%.
  • the seminal plasma protein is a granule prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content is 51.3%.
  • a seminal plasma protein is a tablet prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content is 56.5%.
  • the seminal plasma protein is a dropping pill prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content is 73.2%.
  • the seminal plasma protein is an oral liquid prepared by using an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content is 79.2%.
  • the seminal plasma protein is an injection prepared by the active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content is 55.4%.
  • a seminal plasma protein of more than 3 kDa is a capsule prepared by the active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content of more than 3 kDa is 13.5%.
  • a seminal plasma protein of greater than 3 kDa is a granule prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content of greater than 3 kDa is 18.2%.
  • a seminal plasma protein of more than 3 kDa is a tablet prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content of more than 3 kDa is 20.1%.
  • a seminal plasma protein of more than 3 kDa is a dropping pill prepared from an active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content of more than 3 kDa is 22.6%.
  • the seminal plasma protein of more than 3 kDa is an oral liquid prepared by the active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content of more than 3 kDa is 24.9%.
  • the seminal plasma protein of more than 3 kDa is an injection prepared by the active ingredient for treating lung cancer, breast cancer, colon cancer, cervical cancer, liver cancer or gastric cancer, but is not limited to the above cancer, wherein the seminal plasma protein content of more than 3 kDa is 19.5%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'utilisation de plasma séminal, en particulier une protéine de plasma séminal qui est de plus de 3 kDa, dans la préparation de médicaments pour traiter des cancers tels que le cancer du poumon, le cancer du sein, le cancer colorectal, le cancer du col de l'utérus, le cancer du foie ou le cancer de l'estomac.
PCT/CN2012/076042 2012-04-28 2012-05-25 Utilisation de plasma séminal WO2013159419A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210132294.4 2012-04-28
CN201210132294.4A CN103156884B (zh) 2012-04-28 2012-04-28 精浆的用途

Publications (1)

Publication Number Publication Date
WO2013159419A1 true WO2013159419A1 (fr) 2013-10-31

Family

ID=48580749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/076042 WO2013159419A1 (fr) 2012-04-28 2012-05-25 Utilisation de plasma séminal

Country Status (2)

Country Link
CN (1) CN103156884B (fr)
WO (1) WO2013159419A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167227A (en) * 1979-03-26 1980-12-26 Max Planck Gesellschaft Semen plasmin* its manufacture and bactericide* fungicide* antitumor or rnaasynthesisssuppressing agent containing same
WO2008134919A1 (fr) * 2007-04-30 2008-11-13 Yan Li Ejaculat d'animaux en tant que matière médicinale et utilisations de celui-ci dans des médicaments pour le traitement de maladies telles que des tumeurs, la dépression, etc.
CN102225197A (zh) * 2011-06-13 2011-10-26 陕西精健新星生物医药有限公司 顶体蛋白的用途及提取方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1459761A4 (fr) * 2001-06-08 2005-04-13 Fourth Military Medical Univ Kit pharmaceutique comprenant une proteine de fusion carboxypeptidase humaine dirigee contre un anticorps a chaine simple de proteine plasmatique seminale et promedicament

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167227A (en) * 1979-03-26 1980-12-26 Max Planck Gesellschaft Semen plasmin* its manufacture and bactericide* fungicide* antitumor or rnaasynthesisssuppressing agent containing same
WO2008134919A1 (fr) * 2007-04-30 2008-11-13 Yan Li Ejaculat d'animaux en tant que matière médicinale et utilisations de celui-ci dans des médicaments pour le traitement de maladies telles que des tumeurs, la dépression, etc.
CN102225197A (zh) * 2011-06-13 2011-10-26 陕西精健新星生物医药有限公司 顶体蛋白的用途及提取方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE, YS. ET AL.: "Antiproliferative and Apoptotic Effects of Zinc-Citrate Compound (CIZAR@) on Human Epithelial Ovarian Cancer Cell (OVCAR3)", KOREAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 49, no. 7, 2006, pages 1427 - 1436 *
WANG, SHUANG: "Regular sexual life helps to reduce gynecological diseases", CHINA HEALTH MONTHLY, 2007, pages 47 *

Also Published As

Publication number Publication date
CN103156884B (zh) 2015-02-04
CN103156884A (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
CN109453212B (zh) 一种具有抗癌作用的毛诃子提取物及其有效部位制备方法
Wang et al. Stevioside inhibits inflammation and apoptosis by regulating TLR2 and TLR2-related proteins in S. aureus-infected mouse mammary epithelial cells
US20080260695A1 (en) Composition for prevention and/or treatment of cancer
CN106943432A (zh) 一种脐带间充质干细胞来源的外泌体及其在制备治疗肝癌药物中的应用
WO2022143010A1 (fr) Utilisation de pyridoxal dans la préparation de médicaments pour le traitement du cancer de l'ovaire
CN107759538B (zh) 2,3-环氧-2-壬砜-5,8-二甲氧基-1,4-萘醌及其制备方法和含其的药物
WO2013159419A1 (fr) Utilisation de plasma séminal
WO2022186608A1 (fr) Utilisation anticancéreuse d'extrait de gonades de stichopus japonicus ou de composés dérivés de celles-ci
US10617734B2 (en) STAT3 and ERK signal pathway inhibitor comprising mogrosides and analogs thereof
CN115252599A (zh) 甘草查尔酮a及光甘草定和甘草查尔酮a的组合物在制备治疗结直肠癌的药物中的应用
TWI580690B (zh) The use of multidipins for the manufacture of pharmaceutical compositions for in vivo multipurpose effects
Ma et al. CFNC, a neocryptolepine derivative, inhibited the growth of gastric cancer AGS cells by inhibiting PI3K/AKT signaling pathway
CN107793380B (zh) 2,3-环氧-2-丙砜-5,8-二甲氧基-1,4-萘醌及其制备方法和含其的药物
Liu et al. UNBS 5162 inhibits the proliferation of human A 549 non‐small‐cell lung cancer cells by promoting apoptosis
CN106924253A (zh) 8-丙二氰小檗碱在制备抗肿瘤药物增敏剂中的应用
CN106890189A (zh) 重楼皂苷在制备抗肿瘤药物增敏剂中的应用
CN106176764B (zh) 拟缺香茶菜中2a，3β,19a-三羟基-12烯-28-乌苏酸在制备抗肿瘤药物中的应用
Gao et al. Puerarin leads to K562 cell apoptosis of chronic myelogenous leukemia via induction of autophagy
CN111514133A (zh) 木香烃内酯和/或去氢木香内酯在制备治疗黑色素瘤的药品中的应用
CN111494397B (zh) 麦冬皂苷类化合物在制备预防和治疗肿瘤的药物中的用途
CN115192587B (zh) 一种枸杞子寡糖的新用途
Zhang et al. Combined treatment of polygonatum and Scutellaria baicalensis suppresses lung cancer cell proliferation through inducing ferroptosis
CN111773229B (zh) 川楝素作为吲哚胺2,3-双加氧酶1抑制剂的用途
CN111956632B (zh) 一种抗肿瘤的组合物及其应用
Jiang et al. The Effect of Isoquercitrin on Cell Apoptosis and Cycle for HepG2 Cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12875629

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12875629

Country of ref document: EP

Kind code of ref document: A1